
Sign up to save your podcasts
Or


Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:
By JAMA Network4.4
470470 ratings
Renal cell carcinoma has an estimated lifetime prevalence of 2.3% for men and 1.3% for women in the US. Affected patients in early stages can have >94% cancer-specific survival. Author William Y. Kim, MD, of the University of North Carolina joins JAMA Associate Editor David L. Simel, MD, MHS, to discuss the epidemiology, clinical presentation, pathophysiology, and management of renal cell carcinoma. Related Content:

317 Listeners

700 Listeners

162 Listeners

254 Listeners

886 Listeners

295 Listeners

259 Listeners

3,335 Listeners

38 Listeners

21 Listeners

12 Listeners

11 Listeners

9 Listeners

16 Listeners

19 Listeners

5 Listeners

7 Listeners

1,150 Listeners

30 Listeners

194 Listeners

9 Listeners

92 Listeners

14 Listeners

5 Listeners

512 Listeners

5 Listeners

366 Listeners

428 Listeners

106 Listeners

18 Listeners

373 Listeners

3 Listeners

315 Listeners

271 Listeners